Kenneth W. Rohrbach - Concepedia

Author

Kenneth W. Rohrbach

Bristol-Myers Squibb (United States)

Also Known As

K W Rohrbach, K. Rohrbach, K.W. Rohrbach, Kenneth Rohrbach, Kenneth W Rohrbach, Kenneth W. Rohrbach, Rohrbach, K.W.

Publications

467

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)DuPont (United States)Wilmington University Research Triangle Park Foundation Bristol-Myers Squibb (Germany)

About

Kenneth W. Rohrbach is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	326
2	Social Sciences	6	6	195
3	Biochemistry	5	5	77
4	Natural Sciences	3	3	46
5	Behavioral Sciences	1	1	13

Kenneth W. Rohrbach

Publications

439

Citations

H-Index

Page 1

	Year	Citations
Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor Siew Peng Ho, Lorey K. Takahashi, Valentin Livanov, Molecular Brain Research Factor-2 ReceptorPsychoneuroimmunologyNeuropsychologyNeurobiological MechanismPsychiatry	2001	80
Cognition enhancement by the acetylcholine releaser DuP 996 Leonard Cook, Victor J. Nickolson, George F. Steinfels, Drug Development Research NeuropsychologyDup 996Abstract Dup 996Brain FunctionSynaptic Transmission	1990	63
Discovery of ( <i>R</i> )-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1- <i>a</i> ]isoindol- 6(2 <i>H</i> )-one, a Selective, Orally Active Agonist of the 5-HT <sub>2C</sub> Receptor Dean A. Wacker, Jeffrey Varnes, Sarah E. Malmstrom, Journal of Medicinal Chemistry	2007	33
Ibipinabant attenuates <i>β</i> ‐cell loss in male Zucker diabetic fatty rats independently of its effects on body weight Kenneth W. Rohrbach, Michael A. Thomas, Susan Glick, Diabetes Obesity and Metabolism	2012	32
DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. Larry L. Cook, S W Tam, Kenneth W. Rohrbach Journal of Pharmacology and Experimental Therapeutics	1992	23
Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents Kenneth W. Rohrbach, Song‐Ping Han, Jinping Gan, European Journal of Pharmacology Energy HomeostasisAppetite ControlPhysiologyHypothalamic PeptideNeuropharmacology	2005	20
Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents Saleem Ahmad, Khehyong Ngu, Keith J. Miller, Bioorganic & Medicinal Chemistry Letters ObesityMedicinal ChemistryNovel 5-Ht2c SelectiveMedicinePharmacological Agent	2009	20
Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate William N. Washburn, Mark C. Manfredi, Pratik Devasthale, Journal of Medicinal Chemistry Medicinal ChemistryBiochemistrySar EvolutionNatural SciencesAntiobesity Clinical Candidate	2014	20
Cumulative dose-effect curves in a conflict test with incremental shock James L. Howard, Kenneth W. Rohrbach, Gerald T. Pollard Psychopharmacology MedicineConflict Test	1982	16
In vivo agonist properties of 7‐hydroxy‐N,N‐di‐n‐propyl‐2‐aminotetralin, a dopamine D<sub>3</sub>‐selective receptor ligand John Mcelroy, Kim Zeller, Kelly Amy, Drug Development Research PsychopharmacologyLocomotor ActivityPharmacotherapyDopamine ReceptorsSocial Sciences	1993	16

Page 1